Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
Jonathan D. Oliner,Hosung Min,Juan Leal,Dongyin Yu,Shashirekha Rao,Edward You,Xiu Tang,Haejin Kim,Susanne Meyer,Seog Joon Han,Nessa Hawkins,Robert Rosenfeld,E. Davy,Kevin Graham,Frederick W. Jacobsen,Shirley Stevenson,Joanne Ho,Qing Chen,Thomas Hartmann,Mark Leo Michaels,Michael J. Kelley,Luke Li,Karen C. Sitney,Frank Martin,Ji-Rong Sun,Nancy Zhang,John Lu,Juan Estrada,Rakesh Kumar,Angela Coxon,Stephen Kaufman,James Pretorius,Sheila Scully,Russ Cattley,Marc Payton,Steve Coats,Linh Nguyen,Binodh DeSilva,Anthony Ndifor,Isaac J. Hayward,Robert Radinsky,Tom Boone,Richard Kendall +42 more
Reads0
Chats0
TLDR
In this paper, the authors showed that specific Ang2 inhibition may represent an effective anti-angiogenic strategy for treating patients with solid tumors, and they showed that anti-Ang2 therapy also prevented VEGF-stimulated neovascularization in a rat corneal model of angiogenesis.About:
This article is published in Cancer Cell.The article was published on 2004-11-01 and is currently open access. It has received 505 citations till now. The article focuses on the topics: Angiopoietin receptor & Angiogenesis.read more
Citations
More filters
Journal ArticleDOI
Angiogenesis as a therapeutic target
TL;DR: Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
Journal ArticleDOI
Hypoxia signalling in cancer and approaches to enforce tumour regression
TL;DR: There are new approaches to enforce necrotic cell death and tumour regression by targeting tumour metabolism and pHi-control systems.
Journal ArticleDOI
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.
Michele De Palma,Mary Anna Venneri,Rossella Galli,Lucia Sergi Sergi,Letterio S. Politi,Maurilio Sampaolesi,Luigi Naldini +6 more
TL;DR: It is demonstrated that monocytes expressing the Tie2 receptor (Tie2-expressing monocytes [TEMs]) are a distinct hematopoietic lineage of proangiogenic cells that are selectively recruited to spontaneous and orthotopic tumors and promote angiogenesis in a paracrine manner.
Journal ArticleDOI
Exciting New Advances in Neuro-Oncology The Avenue to a Cure for Malignant Glioma
Erwin G. Van Meir,Constantinos G. Hadjipanayis,Andrew D. Norden,Hui-Kuo G. Shu,Patrick Y. Wen,Jeffrey J. Olson +5 more
TL;DR: There is definite hope that by 2020, new cocktails of drugs will be available to target the key molecular pathways involved in gliomas and reduce their mortality and morbidity, a positive development for patients, their families, and medical professionals alike.
Journal ArticleDOI
Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
TL;DR: The Tie receptors and their angiopoietin (Ang) ligands have been identified as the second vascular tissue-specific receptor Tyr kinase system and provide unique insights into the functions of this vascular signalling system.
References
More filters
Journal ArticleDOI
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre Peter C,Chitra Suri,Pamela F. Jones,Sona Bartunkova,Stanley J. Wiegand,Czeslaw Radziejewski,Debra L Compton,Joyce Mcclain,Aldrich Thomas H,Nick Papadopoulos,Thomas J. Daly,Samuel Davis,Thomas N. Sato,George D. Yancopoulos +13 more
TL;DR: The discovery of a negative regulator acting on Tie2 emphasizes the need for exquisite regulation of this angiogenic receptor system.
Journal ArticleDOI
Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis
Chitra Suri,Pamela F. Jones,Sybill Patan,Sona Bartunkova,Maisonpierre Peter C,Samuel Davis,Thomas N. Sato,George D. Yancopoulos +7 more
TL;DR: It is shown that mice engineered to lack Angiopoietin-1 display angiogenic deficits reminiscent of those previously seen in mice lacking TIE2, demonstrating that AngiopOietIn-1 is a primary physiologic ligand for TIE1 and that it has critical in vivo angiogenesis actions that are distinct from VEGF and that are not reflected in the classic in vitro assays used to characterize VEGf.
Journal ArticleDOI
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Jocelyn Holash,Maisonpierre Peter C,Debra L Compton,Patricia Boland,C. R. Alexander,David Zagzag,George D. Yancopoulos,Stanley J. Wiegand +7 more
TL;DR: Evidence is presented here that a subset of tumors instead initially grows by coopting existing host vessels and regresses, leading to a secondarily avascular tumor and massive tumor cell loss.
Journal ArticleDOI
Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning
Samuel Davis,Aldrich Thomas H,Pamela F. Jones,Ann Acheson,Debra L Compton,Vivek Jain,Terence E Ryan,Joanne Bruno,Czeslaw Radziejewski,Maisonpierre Peter C,George D. Yancopoulos +10 more
TL;DR: The identification of a secreted ligand for TIE2, termed Angiopoietin-1, is reported using a novel expression cloning technique that involves intracellular trapping and detection of the ligand in COS cells.
Journal ArticleDOI
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation.
TL;DR: It is shown that VEGF-mediated capillary invasion is an essential signal that regulates growth plate morphogenesis and triggers cartilage remodeling and VEGf is anessential coordinator of chondrocyte death, chondROclast function, extracellular matrix remodeling, angiogenesis and bone formation in the growth plate.